Junshi Biosciences Reports Final P-III (NEOTORCH) Trial Data of Toripalimab + Chemotherapy for Resectable Stage II-III NSCLC at ESMO 2026

Shots: Junshi Biosciences presented final analysis data from the P-III (NEOTORCH) trial of perioperative toripalimab (240mg, Q3W) + CT vs PBO + CT in pts (n=501) with resectable stage II-III NSCLC at ESMO 2026 (LBA64), published simultaneously in Annals of Oncology At a median follow-up of 48.2mos., EFS improved (HR=0.52; mEFS: NR vs 20.2mos.), with BIPR-assessed MPR of 47% vs 9% & pCR of 26% vs 1%; OS was significantly improved (HR=0.66; p=0.0072), with mOS NR in either arm The safety profile remained manageable with no new signals; NMPA accepted an sNDA in Jul 2026 to expand the indication to resectable stage II-III NSCLC Ref: GlobeNewswire  |   Image: Junshi Biosciences  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Junshi Biosciences Reports Final P-III (NEOTORCH) Trial Data of Toripalimab + Chemotherapy for Resectable Stage II-III NSCLC at ESMO 2026 appeared first on PharmaShots.